证券代码：300482 证券简称：万孚生物 公告编号：2023-059 广州万孚生物技术股份有限公司 关于公司及控股子公司2023年半年度日常关联交易确认 及增加2023年度日常关联交易预计的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、日常关联交易基本情况 （一）日常关联交易履行的审议程序 2023 年 8 月 15 日，广州万孚生物技术股份有限公司（以下简称"公司"） 召开第四届董事会第二十三次会议，经关联董事回避表决，审议通过了《关于公 司及控股子公司 2023 年半年度关联交易确认及增加 2023 年度日常关联交易预 计的议案》。公司第四届监事会第十七次会议审议通过了上述议案，独立董事发 表了明确的事前认可意见和独立意见。 （二）2023 年半年度日常关联交易确认情况 根据第四届董事会第十九次会议和 2022 年年度股东大会审议通过的《关于 公司及控股子公司 2022 年度关联交易确认及 2023 年度日常关联交易预计的议 案》，预计 2023 年度公司及控股子公司与关联方发生的关联交易合计不超过 250,050,000.00 元。 202 ...

广州万孚生物技术股份有限公司 独立董事关于第四届董事会第二十三次会议 的独立意见 我们作为广州万孚生物技术股份有限公司（以下简称"公司"）的独立董事， 根据《公司章程》、《董事会议事规则》、《独立董事工作细则》等相关规章制度的 有关规定，本着审慎的原则，基于独立判断的立场，现就公司第四届董事会第二 十三次会议审议的相关事项发表如下意见： 一、关于公司募集资金存放与实际使用情况专项报告的独立意见 经审阅公司编制的《关于公司募集资金存放与实际使用情况的专项报告》， 经过询问公司相关业务人员、内部审计人员和高级管理人员后，我们认为，公司 编制的《关于公司募集资金存放与实际使用情况的专项报告》内容真实、准确、 完整，不存在虚假记载、误导性陈述和重大遗漏，如实反映了公司 2023 年半年 度募集资金实际存放与使用情况。 2023 年半年度公司募集资金的存放和使用，符合中国证监会、深圳证券交 易所关于上市公司募集资金存放和使用的相关规定，符合公司《募集资金管理办 法》的有关规定，不存在募集资金存放和使用违规的情形。 二、关于 2023 年上半年公司控股股东及其他关联方占用上市公司资金及对 外担保情况的独立意见 2、我们对 ...

| 证券代码：300482 | 证券简称：万孚生物 公告编号：2023-056 | | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | 广州万孚生物技术股份有限公司 第四届监事会第十七次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 广州万孚生物技术股份有限公司（以下简称"公司"）第四届监事会第十七 次会议于 2023 年 8 月 15 日下午 2:00 在公司会议室以现场与通讯相结合的方式 召开，会议通知于 2023 年 8 月 10 日以邮件、电话的方式向全体监事发出。会议 应到监事 3 名，实到 3 名，出席会议人数符合《公司法》和《公司章程》规定。 会议由公司监事会主席吴翠玲女士主持。 经与会监事认真审议，本次会议通过以下议案： 一、审议通过《关于<2023 年半年度报告及其摘要>的议案》 经核查，监事会认为：董事会编制和审核 2023 年半年度报告的程序符合法 律、行政法规以及中国证监会的有关规定，报告内容真实、准确、完整地反映了 公司经营、管理及财务等各方面的实际情况，不存在任何虚假记载、误导性陈述 或 ...

公司负责人（法定代表人）： 王继华 主管会计工作负责人： 余芳霞 会计机构负责人： 彭彩媚 汇总表第 1 页 | | | | 上市公司 | 2023 年 | 2023 年 | 1-6 月 | 2023 年 1-6 | 2023 年 | 1-6 | 2023 年 6 | 月 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 占用方与上市公司 | | | 占用累计发生 | | 月占用资金 | | | 30 | 日 | 占用 | | | 非经营性资金占用 | 资金占用方名称 | | 核算的 | 期初占用 | | | | 月偿还累计 | | | | | 占用性质 | | | | 的关联关系 | 会计科目 | 资金余额 | 金额（不含利 | | 的利息(如 | 发生金额 | | | 末占用 | 形成原因 | | | | | | | | 息） | | 有) | | | | 资金余额 | | | | 控股股东、实际控制 | 无 | | | | | | | | | | | | 非经 ...

| 证券代码：300482 | 证券简称：万孚生物 公告编号：2023-055 | | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | 广州万孚生物技术股份有限公司 第四届董事会第二十三次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 广州万孚生物技术股份有限公司（以下简称"公司"或"本公司"）第四届 董事会第二十三次会议于 2023 年 8 月 15 日上午 10:00 在公司会议室以现场与 通讯相结合的方式召开，会议通知于 2023 年 8 月 10 日以邮件、电话的方式向全 体董事发出。会议应到董事 7 名，实到 7 名，出席会议人数符合《公司法》和《公 司章程》规定。会议由公司董事长王继华女士主持。 经与会董事认真审议，本次会议通过以下议案： 一、审议通过《关于<2023 年半年度报告及其摘要>的议案》 公司《2023 年半年度报告》及其摘要已编制完成，其编制程序符合法律、 行政法规以及中国证监会的有关规定，报告内容真实、准确、完整地反映了公 司经营、管理及财务等各方面的实际情况，不存在任何虚假记载、误导性 ...

| | | 广州万孚生物技术股份有限公司 关于召开 2023 年第一次临时股东大会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 广州万孚生物技术股份有限公司（以下简称"公司"）于 2023 年 8 月 19 日召 开的第四届董事会第二十三次会议审议通过了《关于提请召开 2023 年第一次临 时股东大会的议案》，决定于 2023 年 8 月 31 日（星期四）召开公司 2023 年第一 次临时股东大会，现将本次股东大会的有关事项通知如下： 一、召开会议的基本情况 1、股东大会届次：2023 年第一次临时股东大会。 2、会议召集人：公司董事会。 3、会议召开的合规性：本次股东大会的召开符合有关法律、行政法规、部 门规章、规范性文件和《广州万孚生物技术股份有限公司章程》的有关规定，公 司第四届董事会第二十三次会议已经审议通过召开本次股东大会的议案。 4、会议召开的日期、时间： （1）现场会议召开时间为：2023 年 8 月 31 日（星期四）14:00。 （2）网络投票时间为：2023 年 8 月 31 日 9:15 至 2023 年 8 月 31 日 ...

Financial Performance - The company's revenue for Q1 2023 was ¥831,629,122.23, a decrease of 68.32% compared to ¥2,625,283,985.42 in the same period last year[7] - Net profit attributable to shareholders was ¥203,678,161.27, down 77.46% from ¥903,506,781.16 year-on-year[7] - Basic and diluted earnings per share were both ¥0.46, a decline of 77.56% from ¥2.05 in the same period last year[7] - Total operating revenue for Q1 2023 was CNY 831,629,122.23, a decrease of 68.3% compared to CNY 2,625,283,985.42 in the same period last year[26] - Net profit for Q1 2023 was CNY 202,212,680.82, a decrease of 77.7% compared to CNY 901,709,729.58 in Q1 2022[29] - The total comprehensive income for Q1 2023 was CNY 202,604,008.04, significantly lower than CNY 903,678,461.03 in Q1 2022, highlighting the impact of reduced profitability[32] Cash Flow - The net cash flow from operating activities improved by 37.98%, reaching -¥221,701,390.44 compared to -¥357,477,956.88 in the previous year[7] - The net cash flow from operating activities was -221,701,390.44 CNY, an improvement from -357,477,956.88 CNY in the previous period, indicating a 38% reduction in cash outflow[37] - Total cash inflow from operating activities was 707,399,227.91 CNY, down 41.3% from 1,203,610,658.01 CNY in the previous period[37] - Cash outflow from operating activities totaled 929,100,618.35 CNY, a decrease of 40.5% compared to 1,561,088,614.89 CNY last year[37] - The net cash flow from investing activities was 11,894,625.62 CNY, a significant recovery from -252,852,743.65 CNY in the previous period[37] - Cash inflow from investing activities was 1,120,787,819.86 CNY, down 35.9% from 1,747,447,477.63 CNY in the previous period[37] - Cash outflow from investing activities was 1,108,893,194.24 CNY, a decrease of 44.7% compared to 2,000,300,221.28 CNY last year[37] - The net cash flow from financing activities was -200,348,519.87 CNY, compared to a positive cash flow of 199,910,395.91 CNY in the previous period[37] - The total cash and cash equivalents at the end of the period were 748,525,744.53 CNY, an increase from 584,944,076.03 CNY in the previous period[39] Assets and Liabilities - Total assets at the end of the reporting period were ¥5,917,755,800.57, a decrease of 6.08% from ¥6,301,138,498.06 at the end of the previous year[7] - The company's total liabilities as of Q1 2023 amounted to CNY 1,171,298,113.68, compared to CNY 1,763,580,723.22 in the previous year[28] - Total current assets decreased from CNY 3,350,388,699.00 to CNY 3,214,883,420.68, indicating a decline of approximately 4.05%[23] - Total non-current assets decreased from CNY 2,950,749,799.06 to CNY 2,702,872,379.89, reflecting a decline of about 8.38%[23] - The total assets of the company decreased from CNY 6,301,138,498.06 to CNY 5,917,755,800.57, a reduction of approximately 6.09%[23] - Short-term borrowings significantly decreased from CNY 204,357,852.72 to CNY 3,000,000.00, a decline of about 98.53%[23] Shareholder Information - Total number of common shareholders at the end of the reporting period is 66,785, with the top ten shareholders holding a combined 33.17% of the total share capital[18] - The number of shares held by the top shareholder, Li Wenmei, is 97,843,968, representing 22.01% of the total shares[18] - The company's equity attributable to shareholders increased by 4.84% to ¥4,554,120,777.67 from ¥4,343,755,389.17 at the end of the previous year[7] - The total equity attributable to shareholders of the parent company increased to CNY 4,554,120,777.67 from CNY 4,343,755,389.17 year-on-year[28] Expenses and Income - The company reported a significant decrease in sales revenue primarily due to a reduction in antigen sales[13] - The company experienced a 58.21% reduction in selling expenses, amounting to ¥146,021,066.07 compared to ¥349,408,282.77 in the previous year[13] - Total operating costs for Q1 2023 were CNY 608,061,116.29, down from CNY 1,500,079,621.40 in the previous year, reflecting a significant reduction in expenses[29] - Research and development expenses for Q1 2023 were CNY 94,403,973.82, down from CNY 118,277,455.31 in the previous year, indicating a focus on cost management[29] - The company reported a decrease in sales expenses to CNY 146,021,066.07 from CNY 349,408,282.77 year-on-year, reflecting improved operational efficiency[29] - The company recorded other income of CNY 8,703,414.00 in Q1 2023, compared to CNY 2,095,331.29 in the same period last year, indicating potential growth in ancillary revenue streams[29] - Interest income increased by 224.51% to ¥2,529,282.86, up from ¥779,407.79 year-on-year[13] - The company received government subsidies amounting to ¥9,349,383.14, contributing positively to its financial performance[8] Inventory and Receivables - The company's inventory increased from CNY 399,967,713.19 to CNY 466,705,476.95, representing an increase of approximately 16.67%[23] - The total receivables increased from CNY 540,161,426.51 to CNY 564,452,271.95, indicating a growth of about 4.67%[23] - The company reported a total of 1,283,682,046.63 in trading financial assets at the end of the reporting period, up from CNY 938,071,800.35 at the beginning of the year[23]

证券代码：300482 证券简称：万孚生物 债券代码：123064 债券简称：万孚转债 广州万孚生物技术股份有限公司投资者关系活动记录表 | 投 资 者 关 系活动 | □特定对象调研 □分析师会议 | | --- | --- | | 类别 | □媒体采访□业绩说明会 | | | □新闻发布会 □路演活动 | | | □现场参观 | | | √其他：电话会议，投资者线上交流会 | | 参 与 单 位 名称及 | 广发证券股份有限公司、海通证券股份有限公司、华创证券股份有限公司等 | | 人员姓名 | | | 时间 | 2023 年 3 月 31 日 | | 地点 | 电话会议 | | 上 市 公 司 接待人 | 董事长：王继华 | | 员姓名 | 董事会秘书：胡洪 | | | 财务总监：余芳霞 | | | 证券事务代表：华俊 | | | 一、2022 年全年经营情况介绍： | | | 2022 年，对万孚生物来说，是成立三十周年的而立之年，也是继往开来、 | | | 承前启后的一年。报告期内，公司实现营业收入 56.8 亿元，比上年同期增长 | | | 69%；归属于上市公司股东的净利润 11.97 亿元，比 ...

Financial Performance - The company's operating revenue for 2022 reached ¥5,680,513,174.77, representing a 69.01% increase compared to ¥3,361,043,277.33 in 2021[25]. - Net profit attributable to shareholders for 2022 was ¥1,196,968,338.20, an increase of 88.67% from ¥634,433,145.20 in the previous year[25]. - The net profit after deducting non-recurring gains and losses was ¥1,105,006,709.65, up 100.70% from ¥550,583,020.43 in 2021[25]. - Cash flow from operating activities for 2022 was ¥1,682,171,310.01, a significant increase of 152.98% compared to ¥664,930,290.53 in 2021[25]. - Basic earnings per share for 2022 were ¥2.71, reflecting an increase of 89.51% from ¥1.43 in 2021[25]. - Total assets at the end of 2022 amounted to ¥6,301,138,498.06, a 29.76% increase from ¥4,855,824,467.37 at the end of 2021[25]. - The net assets attributable to shareholders at the end of 2022 were ¥4,343,755,389.17, up 29.54% from ¥3,353,100,618.30 in 2021[25]. - The company's non-operating income totaled ¥91,961,628.55 in 2022, an increase of 9.5% from ¥83,850,124.77 in 2021[31]. - The fair value changes and investment income from trading financial assets reached ¥69,780,497.57, up from ¥53,555,315.92 in 2021, indicating a significant increase of 30.4%[31]. Market Presence and Expansion - In 2022, the company's overseas revenue accounted for 49.43% of total operating income, indicating significant reliance on international markets[8]. - The company has established nine major technology platforms, covering various diagnostic fields, and products are sold in over 140 countries and regions[5]. - The company has expanded its international market presence since 2004, adhering to quality control standards from developed countries[55]. - The company operates a dual sales model, primarily using distribution in China and focusing on direct sales for self-testing products through e-commerce platforms[46][48]. - The international market contributes significantly to revenue, with the immunofluorescence and immunochromatography platforms being the main revenue drivers, and a noticeable increase in the proportion of quantitative products[52]. - The company is actively pursuing international market expansion with a structured approach to improve operational capabilities in key overseas regions[153]. - The company is establishing local operations in key countries to enhance service quality and support for small laboratories abroad[154]. Product Development and Innovation - The company has a diversified product line in the POCT industry, focusing on cardiovascular diseases, infections, and drug abuse testing[5]. - The company is continuously innovating its product pipeline, focusing on chronic diseases and common illnesses to enhance competitiveness[67]. - The company developed 111 new products during the reporting period, including 31 on the colloidal gold platform and 44 on the immunofluorescence platform[98]. - The company’s new COVID-19 antigen test received WHO EUL certification, enhancing its market potential[84]. - The company’s HIV self-test product obtained WHO PQ certification, aiming to improve global HIV testing coverage[103]. - The company is expanding its product lines in chemical luminescence, molecular diagnostics, and pathology diagnostics, focusing on critical and chronic diseases[151]. Regulatory and Compliance - The company emphasizes compliance with international quality standards, having received multiple certifications from FDA and CE[6]. - The company has received IVDR certification, enhancing its competitive advantage in the European market, but ongoing R&D capabilities are crucial for future growth[5]. - The company obtained the TÜV:SÜD certification for the MDSAP quality management system, confirming compliance with regulations from the USA, Canada, Brazil, and Australia[56]. - The company’s quality management system met all regulatory requirements, with 34 audits and 16 self-inspections conducted during the reporting period[102]. Risks and Challenges - The company faces risks related to new product development, registration, and certification due to stricter regulatory policies in China, the EU, and the US[5]. - The implementation of the "two-invoice system" in some regions may impact the company's distribution network and sales performance[8]. - Currency fluctuations may affect the company's financial performance due to its substantial foreign sales[8]. - The company has experienced rapid business expansion, which may lead to quality control risks if risk management does not keep pace[6]. Governance and Management - The company has held three shareholder meetings during the reporting period, reviewing 29 proposals to ensure compliance with governance standards[158]. - The board of directors consists of seven members, including three independent directors, ensuring compliance with relevant laws and enhancing decision-making capabilities[159]. - The company has a diverse management team with members holding various academic qualifications, including medical and financial degrees[173][174]. - The company has established performance evaluation standards and incentive mechanisms for senior management, ensuring transparency in appointments[162]. - The company maintains independent operations in terms of assets, personnel, finance, and business, complying with relevant laws and regulations[163]. Research and Development - The company invested 446.85 million yuan in R&D, accounting for 7.87% of total revenue[92]. - The company's R&D investment amounted to ¥446,853,040.79 in 2022, representing 7.87% of total revenue, a decrease from 13.66% in 2021[121]. - The number of R&D personnel decreased by 3.13% to 805 in 2022, with a notable drop in master's degree holders by 11.33%[121]. - The company has been actively involved in research and development, with its general manager overseeing product and operational centers[169]. Strategic Initiatives - The company emphasizes strategic collaboration and market expansion through both organic growth and acquisitions to maintain a competitive edge[45]. - The company has formed a strategic layout of an "ecological circle," expanding its business through mergers and strategic partnerships[75][76]. - The company follows a "dual circulation" development strategy, focusing on both domestic and international markets to promote balanced and rapid growth[149]. - The company emphasizes a dual-core business system of B2B and B2C, with a focus on innovation-driven and scenario-oriented product strategies[149]. Shareholder Engagement - The company plans to distribute a cash dividend of 5 RMB per 10 shares (including tax) to all shareholders as part of its profit distribution plan for 2022[9]. - The first temporary shareholders' meeting in 2022 had a participation rate of 50.69%[165]. - The annual shareholders' meeting in 2021 had a participation rate of 48.36%[165]. - The second temporary shareholders' meeting in 2022 had a participation rate of 35.79%[165].

关于举办2022年度业绩网上说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 广州万孚生物技术股份有限公司（以下简称"公司"）《2022 年年度报告》 及其摘要于 2023 年 3 月 31 日刊登在中国证监会指定的创业板信息披露网站巨潮 资讯网（http://www.cninfo.com.cn）、《证券时报》、《中国证券报》、《证 券日报》和《上海证券报》。 | 证券代码：300482 | 证券简称：万孚生物 公告编号：2023-023 | | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | 为了让广大投资者进一步了解公司 2022 年年度经营情况，公司将于 2023 年 3 月 31 日（星期五）15:00-17:00 在深圳证券信息有限公司提供的网上平台举行 2022 年度业绩网上说明会。本次说明会将采用网络远程方式举行，投资者可登陆 "全景•路演天下"（http://rs.p5w.net）参与本次业绩说明会。 出席本次业绩说明会的人员有：公司董事长王继华女士，独立董事陈锦棋先 生，董事会秘书胡洪女士，财务负责 ...